TEMOBIC : Phase II Trial of Neoadjuvant Chemotherapy for Unresectable Anaplastic Gliomas: An ANOCEF Study

Emeline Tabouret (1, 2) , Michel Fabbro , Didier Autran , Khe Hoang‐xuan , Luc Taillandier , François Ducray , Maryline Barrie , Marc Sanson , Christine Kerr , Stephanie Cartalat‐carel , Anderson Loundou , Remy Guillevin , Karima Mokhtari , Dominique Figarella‑branger (1, 3) , Jean‐yves Delattre , Olivier Chinot (1, 2)

1 INP - Institut de neurophysiopathologie
2 Service d’Oncologie Médicale [Hôpital de la Timone - APHM]
3 ACPNP - Service d'Anatomo-Cyto-Pathologie et de NeuroPathologie [Hôpital de la Timone - APHM]

Domaines: Sciences du Vivant [q-bio]

Emeline Tabouret, Michel Fabbro, Didier Autran, Khe Hoang‐xuan, Luc Taillandier, et al.. TEMOBIC : Phase II Trial of Neoadjuvant Chemotherapy for Unresectable Anaplastic Gliomas: An ANOCEF Study. Oncologist, 2021, ⟨10.1002/onco.13765⟩. ⟨hal-03253040⟩